101 Federal Street, Suite 1900 8980 Lakes at

INFORM GENOMICS ANNOUNCES COMPLETION OF PRIVATE PLACEMENT
Boston, MA–May 13, 2015. Inform Genomics, Inc, a company that utilizes a proprietary analytic platform to develop genomicbased, precision medicine products, today announced the completion of a $2.6 million private placement of preferred stock.
Inform Genomics anticipates using the net proceeds from the financing to advance the development of its lead programs in
oncology supportive care, including OnPARTTM and HSCT/MucositisTM, developing its proprietary analytic platform, and for
general corporate purposes, including patent filings and working capital.
“We are pleased with the interest from our existing and new investors,” said Ed Rubenstein, MD, President and CEO of Inform
Genomics. “This capital will help us advance our business and has allowed us to begin hiring our “C”-suite officers and to
continue the progress for our product development programs.”
About Inform Genomics
Inform Genomics, Inc, is a company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine
products. Our product candidates are designed to predict, with a high degree of accuracy, clinically important outcomes that
assist physicians and their patients in making individualized medical decisions.
Our current focus is in oncology supportive care, with two product candidates in development. Each is designed to predict a
patient’s risk for developing common chemotherapy-related side effects. Knowing an individual’s risk in advance of therapy can
further inform clinical decision-making and reduce the high patient, clinical, and economic burden of chemotherapy-related side
effects.
Product Development Program
OnPART™ (Oncology Preferences And Risk of Toxicity). OnPART™ has completed its first phase of development and has
shown it can accurately predict a patient’s risk for six clinically significant and costly side effects due to chemotherapy regimens.
These side effects include nausea and vomiting, moderate-to-severe diarrhea, peripheral neuropathy, oral mucositis, cognitive
dysfunction, and fatigue. OnPART™ incorporates genomic risks for side effects while also quantifying a patient’s willingness to
tolerate them (Preference Assessment Inventory©). OnPART™ has also shown biologic validity for each of its predictive
networks. A multicenter US study is planned to prepare it for commercialization.
The Hematopoietic Stem Cell Transplant (HSCT)/Mucositis™ Product Candidate. As many as 40% of patients undergoing
high-dose chemotherapy conditioning regimens for stem cell transplantation will go on to develop moderate-to-severe oral
mucositis, with an attendant increase of morbidity and mortality. Our HSCT/Mucositis™ product candidate is designed to help
physicians identify this at-risk group so that primary prevention can be part of the supportive care strategy before
chemotherapy—thus minimizing the clinical and economic impact of this debilitating side effect. In its first phase of development,
this product candidate demonstrated that it can predict, with a high degree of accuracy, a patient’s risk for developing oral
mucositis. A multicenter US study is planned to prepare it for commercialization.
For more information, please visit www.informgenomics.com.
Contact:
Inform Genomics
Ed Rubenstein, MD, President and CEO
[email protected]
101 Federal Street, Suite 1900
Boston MA 02110
8980 Lakes at 610 Drive, Suite 100
Houston TX 77054